Pfizer: Ibrance fails to meet endpoint in breast cancer

(CercleFinance.com) - Pfizer said on Friday that its Ibrance cancer drug failed to meet its primary endpoint of improving survival in women with early breast cancer in a late-stage clinical trial.


The 1,250-patient randomised, placebo-controlled phase-3 study compared one year of Ibrance plus at least five years of standard therapy, to placebo plus at least five years of standard therapy.

Pfizer said the trial did not meet the primary endpoint of improved disease-free survival in these women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer who have residual invasive disease after chemotherapy.

While the US drugmaker said it was "disappointed" with this result, it also said it was looking forward to continuing to work with research partners to understand the development of next-generation CDK inhibitors, such as Ibrance, in early breast cancer.

Copyright (c) 2020 CercleFinance.com. All rights reserved.